Question: The joint cost of blocking NGF, dose by dose, on a target whose receptor interface is solved
What the composite joint safety endpoint was made of, and which patients were at risk
Collecting findings
0/2 publication-ready
Findings metrics
—
total
—
verified
—
pending
—
rejected